[ad_1]
A new study, published in Antimicrobial Agents and Chemotherapy and conducted by a research consortium led by the University of Liverpool, has developed a new treatment option for some multidrug-resistant infections.
Antimicrobial resistance (AMR) is a serious global threat to human health that makes it even harder to treat infections before, and according to the World Health Organization, 25,000 deaths per year in the European Union alone.
Gram-negative bacteria (GNB) are a group of bacteria of medical importance that can cause serious infections in NHS patients. They are increasingly resistant to several antibiotics and, in some cases, incurable. The emergence of Gram-negative MDR bacteria is a serious and growing threat to public health.
Carbapenems are a clbad of highly effective antibiotic agents commonly used for the treatment of serious or high-risk bacterial infections. This clbad of antibiotics is usually reserved for known or suspected multidrug-resistant bacterial infections. Carbapenems are usually administered by intravenous injection, which requires hospitalization and placement of an intravenous catheter.
The Tebipenem pivoxil hydrobromide (SPR994) is a new carbapenem developed by Spero Therapeutics and developed as an oral antimicrobial agent. Such treatment may facilitate hospital discharge sooner or the possibility of treating complex infections in the community.
The consortium, led by Professor William Hope of the Center for Antimicrobial Pharmacodynamics at the University of Liverpool, used a range of experimental model systems to identify the appropriate dosage to study in a large clinical trial phase III dealing with the registration of patients with complicated urinary tract infections. This phase III study is a global multicentre study that is currently recruiting patients. The team used a combination of laboratory models that mimic human disease and a combination of mathematical and statistical techniques to predict an appropriate dosage. Such an approach maximizes the chances that the right dose will be studied the first time.
An accelerated drug development program of this type ensures that new antibiotics are available to NHS patients as soon as possible and offers new options for the treatment of infections for which there is currently little or no therapeutic choice.
Hope said, "This program, conducted in collaboration with Spero Therapeutics, is a prime example of the core mission of the Center for Antimicrobial Pharmacodynamics, which is to accelerate the development of new antibiotics for patients with AMR." Working with Spero Therapeutics The consortium's experience in developing antimicrobial drugs within the consortium will ensure tebipenem can be a future treatment option for NHS patients and the world. "
"We are fortunate to be working with the Center of Antimicrobial Pharmacodynamics on the dose selection of our pivotal Phase 3 clinical trial, as its design has greatly benefited from their experience," said Tom Parr, Scientific Director of Spero Therapeutics. "At Spero, we are committed to addressing the serious unmet need for multidrug-resistant infections and we look forward to providing updates on our Phase III trial on SPR994 in complicated urinary tract infections."
Source: University of Liverpool
Source link
